S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
This Stock Could Go Up 66% or More. (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
NASDAQ:ACGN

Aceragen (ACGN) Stock Forecast, Price & News

$0.38
0.00 (0.00%)
(As of 09/1/2023)
Compare
Today's Range
$0.38
▼
$0.38
50-Day Range
$0.38
▼
$1.51
52-Week Range
$0.36
▼
$16.00
Volume
N/A
Average Volume
N/A
Market Capitalization
$3.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

ACGN stock logo

About Aceragen (NASDAQ:ACGN) Stock

Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

ACGN Price History

ACGN Stock News Headlines

August 26, 2023 | ca.finance.yahoo.com
ACGN - Aceragen, Inc.
August 8, 2023 | msn.com
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.16%
September 24, 2023 | Stansberry Research (Ad)
Experts: NVIDIA Now "Too Big to Succeed"
Several of the market’s top analysts are sounding the alarm that NVIDIA’s share price may have reached its breaking point.
August 4, 2023 | finance.yahoo.com
Aceragen, Inc. to Delist from The Nasdaq Stock Market
July 12, 2023 | bizjournals.com
Cash-strapped public company in Durham moves to liquidate. Will shareholders get anything?
July 11, 2023 | bizjournals.com
Investor wants its money back as Durham firm weighs bankruptcy
June 29, 2023 | chron.com
Aceragen: Q1 Earnings Snapshot
May 30, 2023 | finance.yahoo.com
Aceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing
September 24, 2023 | Stansberry Research (Ad)
Experts: NVIDIA Now "Too Big to Succeed"
Several of the market’s top analysts are sounding the alarm that NVIDIA’s share price may have reached its breaking point.
April 17, 2023 | bizjournals.com
Durham public company begins furloughs as it searches for capital
March 30, 2023 | benzinga.com
Aceragen Stock (NASDAQ:ACGN), Guidance and Forecast
March 5, 2023 | barrons.com
Aceragen Inc.
March 1, 2023 | markets.businessinsider.com
JMP Securities Keeps Their Buy Rating on Aceragen (ACGN)
February 6, 2023 | finance.yahoo.com
Aceragen Announces Recommendation of Data Monitoring Committee in Terra Study
See More Headlines
Receive ACGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aceragen and its competitors with MarketBeat's FREE daily newsletter.

ACGN Company Calendar

Last Earnings
6/29/2023
Today
9/24/2023
Next Earnings (Estimated)
9/26/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACGN
CUSIP
N/A
CIK
861838
Web
www.iderapharma.com
Phone
(484) 348-1600
Fax
617-679-5592
Employees
26
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-23,360,000.00
Net Margins
N/A
Pretax Margin
-654.13%
Return on Equity
-215.27%
Return on Assets
-53.04%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.32
Quick Ratio
0.32

Sales & Book Value

Annual Sales
$4.86 million
Price / Sales
0.66
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.24 per share
Price / Book
0.12

Miscellaneous

Outstanding Shares
8,420,000
Free Float
6,196,000
Market Cap
$3.20 million
Optionable
Not Optionable
Beta
1.10
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. John C. Taylor (Age 52)
    Pres, CEO & Director
    Comp: $444.06k
  • Ms. Gwen Thomas
    Associate Director of HR, Fin. & Admin.
  • Ms. Christina Amendola
    Director of HR
  • Mr. Brian Jackey
    Sr. VP of Technical Operations
  • Ms. Deepa Nagpal
    Global Head of Quality
  • Dr. Shah Rahimian M.D.
    Ph.D., Medical Director & Global Clinical Lead for Oncology
  • Dr. Joanna Caroline Horobin Ch.B (Age 68)
    M.B., Advisor
  • Mr. Louis J. Arcudi III (Age 62)
    M.B.A., MBA, Adviser

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













ACGN Stock - Frequently Asked Questions

How have ACGN shares performed in 2023?

Aceragen's stock was trading at $5.21 at the start of the year. Since then, ACGN stock has decreased by 92.7% and is now trading at $0.38.
View the best growth stocks for 2023 here.

When is Aceragen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 26th 2023.
View our ACGN earnings forecast.

How were Aceragen's earnings last quarter?

Aceragen, Inc. (NASDAQ:ACGN) released its earnings results on Thursday, June, 29th. The company reported ($2.94) earnings per share for the quarter. The business had revenue of $2.47 million for the quarter.

What is Aceragen's stock symbol?

Aceragen trades on the NASDAQ under the ticker symbol "ACGN."

How do I buy shares of Aceragen?

Shares of ACGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aceragen's stock price today?

One share of ACGN stock can currently be purchased for approximately $0.38.

How much money does Aceragen make?

Aceragen (NASDAQ:ACGN) has a market capitalization of $3.20 million and generates $4.86 million in revenue each year.

How can I contact Aceragen?

Aceragen's mailing address is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. The official website for the company is www.iderapharma.com. The company can be reached via phone at (484) 348-1600, via email at ir@iderapharma.com, or via fax at 617-679-5592.

This page (NASDAQ:ACGN) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -